Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 5%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.42 per share when it actually produced earnings of $0.55, delivering a surprise of 30.95%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Halozyme Therapeutics
, which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $102 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 5.05%. This compares to year-ago revenues of $121.7 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.
Halozyme Therapeutics shares have lost about 18.6% since the beginning of the year versus the S&P 500’s decline of -8.8%.
What’s Next for Halozyme Therapeutics?
While Halozyme Therapeutics has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company’s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this
earnings release
, the estimate revisions trend for Halozyme Therapeutics: unfavorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.49 on $126.92 million in revenues for the coming quarter and $2.15 on $546.17 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical – Biomedical and Genetics is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021. The results are expected to be released on March 3.
This biopharmaceutical company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +30.4%. The consensus EPS estimate for the quarter has been revised 3.2% higher over the last 30 days to the current level.
Arbutus Biopharma’s revenues are expected to be $3.39 million, up 41.6% from the year-ago quarter.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year’s 2021
Zacks Top 10 Stocks
portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report